Tokyo, June 16 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061922) titled 'Discovery of serum proteome biomarkers and integration with pancreatitis-related gene polymorphisms for prediction of post-ERCP pancreatitis' on June 15.
Study Type:
Observational
Primary Sponsor:
Institute - Juntendo University
Condition:
Condition - post ERCP pancreatitis
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - To identify serum proteome biomarkers associated with the development of post-ERCP pancreatitis (PEP) and to obtain foundational knowledge for constructing a PEP prediction model through integrated analysis with pancreatitis-related gene polymorphisms.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
<
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients aged 20 years or older who are hospitalized at Juntendo University Hospital, Nerima Hospital, or Urayasu Hospital and are scheduled to undergo or have previously undergone ERCP for the diagnosis or treatment of hepatobiliary-pancreatic diseases, and who have provided written informed consent after receiving a thorough explanation of the study
Key exclusion criteria - Patients from whom written informed consent cannot be obtained, or those deemed ineligible by the principal investigator
Target Size - 600
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2024 Year 07 Month 18 Day
Date of IRB - 2024 Year 07 Month 18 Day
Anticipated trial start date - 2027 Year 01 Month 01 Day
Last follow-up date - 2030 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070855
Disclaimer: Curated by HT Syndication.
